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Background: During esophagectomy, laparoscopy can be used together with thoracoscopy, but it 
is not known whether a combined thoracoscopic-laparoscopic procedure is associated with fewer 
postoperative complications than open esophagectomy, and without compromising oncological 
outcome. 
Methods: This was a longitudinal cohort study that included 185 esophageal-cancer patients: 72 
who underwent combined thoracoscopic-laparoscopic esophagectomy (TLE), 34 who underwent 
thoracoscopic esophagectomy (TE), and 79 who underwent open esophagectomy (OE), between 
January 2002 and May 2010. The main outcome measures were postoperative respiratory and 
overall complications. The secondary outcome was 2-year relapse-free survival (RFS). 
Results: Respiratory complications occurred in 9 patients who underwent TLE, 13 who 
underwent TE, and 31 who underwent OE. TLE was associated with fewer respiratory 
complications (TLE vs OE: odds ratio [OR], 0.22; 95% confidence interval [CI], 0.09-0.53 and 
TE vs OE: OR, 0.71; 95%CI, 0.29-1.76). Overall complications occurred in 34 patients who 
underwent TLE, 20 who underwent TE, and 54 who underwent OE. TLE was associated with 
fewer overall complications (TLE vs OE: OR, 0.47; 95%CI, 0.23-0.94 and TE vs OE: OR, 0.51; 
95%CI, 0.21-1.25). The 2-year RFS percentages were similar among the three groups: 71.6% for 
TLE, 57.7% for TE, and 58.3% for OE (TLE vs OE: hazard ratio, 0.65; 95%CI, 0.35-1.20 and 
TE vs OE: hazard ratio, 0.91; 95%CI, 0.45-1.82, respectively).  
Conclusions: Unlike TE, TLE was associated with fewer postoperative complications than was 
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Abbreviations: 
ASA-PS: American Society of Anesthesiology Physical Status Classification 
CI: Confidence interval 
CTCAE: Common Terminology Criteria for Adverse Events 
FEV1%: Forced expired volume in the first second, as a percentage of the forced vital capacity 
MIE: Minimally invasive esophagectomy 
OE: Open esophagectomy 
OR: Odds ratio 
RFS: Relapse-free survival 
TNM: Tumor Node Metastasis classification 
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Introduction 
In patients with esophageal cancer, minimally invasive esophagectomy (MIE) can be 
used to reduce surgical invasiveness, gain a better operative field, and lessen perioperative 
complications. MIE is believed to entail less blood loss and shorter hospital stays than 
conventional open esophagectomy (OE). The superiority of MIE over OE with regard to 
postoperative complications has been suggested by several meta-analyses [1-3] and comparative 
studies [4-7]. However, it is not clear whether MIE provides these benefits without 
compromising oncological outcome. 
Furthermore, there is no consensus regarding the optimal method for MIE. The 
techniques used can be thoracoscopic, laparoscopic, or both, and the combined technique has 
been directly compared with the others only rarely [6, 8, 9]. Specifically, the additional benefit of 
laparoscopy is unclear. 
We therefore studied whether incorporating laparoscopy into MIE for esophageal cancer 
could reduce the postoperative respiratory and overall complications without compromising 
2-year relapse-free survival. 
 
Patients and Methods 
Preoperative patient assessment and definition of procedures 
This longitudinal cohort study was done at the Department of Surgery, Kyoto University 
Hospital, with data collected over more than 8 years. It was approved by the ethics committee at 
Kyoto University. All patients had detailed preoperative risk assessments based on clinical 
presentation, chest radiography, electrocardiography, and pulmonary function tests. Preoperative 
tumor staging was based on physical examination, radiologic examination (computed 
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tomography and/or magnetic resonance imaging), upper gastrointestinal series, ultrasonography, 
and endoscopy. 
We used three procedures: combined thoracoscopic-laparoscopic esophagectomy (TLE), 
thoracoscopic esophagectomy (TE), and open esophagectomy (OE). Through August 2005, all 
esophagectomies at our hospital were done with an open transthoracic approach (OE). In 
September 2005, we started using thoracoscopic procedures (TLE or TE), and have continued 
using these techniques. The indications for OE changed with the introduction of thoracoscopic 
procedures, and they differ from the indications for TLE or TE. Before thoracoscopic procedures 
were introduced, OE was indicated in patients with T1 to T3 (TNM classification (sixth edition)) 
and technically resectable T4 tumors (those with invasion of adjacent structures) irrespective of 
lymph node metastasis, previous chemoradiation therapy, or previous esophageal resection. 
Starting in September 2005, TLE or TE was indicated only in those with T1 to T3 tumors. OE 
was indicated only in the remaining patients: those with previous chemoradiation therapy, 
previous esophageal resection, or T4 tumor. Irrespective of the type of thoracic procedure, the 
surgeon’s preference determined whether a patient underwent laparotomy or laparoscopy. 
 
Eligible patients for the analyses 
We reviewed the records of 243 patients who had histologically proven primary 
esophageal cancer and who underwent first esophagectomy between January 2002 and May 2010. 
To reduce imbalances in patient’s clinical characteristics between procedures, only data from 
patients with T1 to T3 tumors, which is also the indication for TLE or TE, were eligible for the 
analyses. By that criterion 195 patients were eligible, and the remaining 48 were excluded. Ten 
patients who underwent thoracotomy-laparoscopy were also excluded, and thus the remaining 
6 
total was 185. The TLE group comprised 72 patients, the TE group 34, and the OE group 79 
(Figure 1). 
The data were analyzed by intention-to-treat. That is, any patients who required 
conversion from TLE to OE or TE because of intraoperative trauma were considered to belong to 
the TLE group. 
 
Surgical procedure 
The thoracoscopic approach was defined as thoracoscopic mobilization of the esophagus 
and regional lymphadenectomy without use of mini-thoracotomy, as reported previously [10, 11]. 
For thoracoscopic mobilization, patients were placed in the left lateral decubitus position or the 
prone position. The regional lymph nodes removed were the mediastinal (paraesophageal, 
paratracheal, subcarinal, supradiaphragmatic, and para–recurrent-laryngeal-nerve) and perigastric 
nodes. In patients with an upper esophageal tumor or metastases to the 
para–recurrent-laryngeal-nerve lymph nodes, the cervical lymph nodes were also removed.  
Subsequently, patients were placed in the supine position for the gastric mobilization to 
obtain complete en bloc resection with upper abdominal lymph nodes. The abdominal procedure 
was done either by laparoscopic (endoscopic or hand-assisted endoscopic) surgery, or by open 
laparotomy. In the laparoscopic approach, after the first port was inserted through the umbilicus 
and CO2 pneumoperitoneum at 8 mmHg was established, four operating ports were placed. The 
greater omentum, gastrosplenic ligament, and short gastric vessels were cut. The esophagus was 
dissected all around at the level of the hiatus, and mobilized with preservation of the right 
gastroepiploic vessels. Then, laparotomy within 5 cm was done to remove the specimen. In the 
open approach, an upper abdominal midline incision was made. An incision was made on the left 
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side of the neck, and then the prepared stomach was pulled up via the posterior mediastinal route, 
an intrathoracic route, or a retrosternal route, and a colon conduit was created through the 
antethoracic or retrosternal route. 
The thoracotomy approach comprised open transthoracic esophageal mobilization using a 
three-incision technique as previously reported [12]. A right posterolateral thoracotomy was done, 
followed by laparoscopy or laparotomy for esophageal dissection and abdominal 
lymphadenectomy. Reconstruction was similar to that done with the thoracoscopic approach. 
No patients underwent pyloroplasty, and no feeding jejunostomy tubes were placed. 
 
Perioperative management 
The procedures were done under a combination of epidural and general anesthesia. A 
double-lumen endotracheal tube was used for single-lung ventilation. At the beginning of the 
operation, 125 mg of methylprednisolone was administered intravenously to attenuate 
intraoperative surgical stress responses and to prevent postoperative complications [13]. 
Immediately after the operation, all patients were routinely admitted to the ICU and placed on 
mechanical ventilation overnight. The management of all the patients was in the same 
environment using intensive care, and the same principles of care were applied. After extubation 
on the next day, patients received respiratory physiotherapy to aid expectoration of any retained 
secretions. Bronchoscopic suction was done when necessary. For postoperative analgesia, 




The pathological classifications of the primary tumor, the degree of lymph node 
involvement, and the presence of organ metastases were defined according to the TNM 
classification (sixth edition), and R classification was used to describe the extent of residual 
disease after esophagectomy (R0: no residual tumor, R1: microscopic residual tumor, R2: 
macroscopic residual tumor) [14]. 
 
Outcomes 
The main outcomes of interest were respiratory and overall complications that occurred 
within 30 days of the operation. The secondary outcome was 2-year relapse-free survival (RFS). 
Respiratory complications were selected from complications higher than grade 2 according to the 
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) 
version 3.0 (adult respiratory distress syndrome, pneumonia, pleural effusion, atelectasis, 
bronchopulmonary hemorrhage, cough, hiccups, aspiration, pneumothorax, and respiratory tract 
fistulae [supplementary material 1]) because these were considered to be clinically important. 
Cases of pleural effusion and pneumothorax were included only if they appeared after 
withdrawal of the thoracic drainage tube. Cases of atelectasis were included only if they were 
confirmed by chest radiography or bronchoscopy. 
Overall complications were, in addition to the respiratory complications described above, 
cardiac or liver dysfunction or failure, stroke, intestinal fistulae, anastomotic leakage, 
chylothorax, perforation of the conduit, anastomotic stenosis, ileus, wound infection, 
intraoperative trauma, intraoperative bleeding, and palsy of the recurrent laryngeal nerve 
(supplementary material 1). Information on these complications, and on death within 30 days of 
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the operation, was extracted from medical records by two reviewers who worked independently 
and were blinded to the surgical procedures (Y. Kinjo and Y. Kataoka). 
Two-year RFS was ascertained only for the patients with R0. The duration used was the 
duration from the date of the surgery until the date of either death (due to any cause) or of the 
first recurrence confirmed by diagnostic imaging. 
 
Statistics and survival analysis 
Continuous variables were expressed as mean ± SD when normally distributed or as 
median and range when non-normally distributed. The three groups were compared with 
one-way ANOVA, Kruskal-Wallis test, or chi-square test, as appropriate. Logistic-regression 
models were used to compare the occurrence of postoperative complications between the groups. 
RFS curves were estimated by the Kaplan–Meier method, and differences between them were 
compared with the log-rank test. The Cox proportional-hazard model was used to compare the 
RFS among the three groups. Variables with a p value less than 0.20 in the bivariate analyses 
were included in the multivariate analyses. All p values less than 0.05 were considered 
statistically significant. All analyses were done with STATA statistical software, version 11.0 
(Stata, College Station, TX, USA). 
 
Results 
Patient characteristics and surgical outcomes 
The clinical and pathologic characteristics of the patients are shown in Table 1. There 
were no significant differences in age, sex, body mass index, smoking history, or FEV1%. The 
prevalence of a history of neoadjuvant chemotherapy varied between groups: TLE > TE > OE. 
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The mean preoperative serum albumin and the proportion of patients with squamous cell 
carcinoma were higher in the TLE group. There was no significant difference in pathological 
TNM staging between the groups. 
The details of the surgical procedures are shown in Table 2. There was no significant 
difference in the field of lymphadenectomy. No patient in the TLE or the TE group had 
intrathoracic anastomosis. Use of stomach conduit and use of hand-sewing were more common 
in the TLE group. For the thoracoscopic procedure, the prone position was used in 16 patients; 13 (18%) 
in the TLE group and 3 (9%) in the TE group. 
The intraoperative and postoperative surgical outcomes are shown in Table 3. The 
thoracic procedure took more time in the TLE group than in the TE and OE groups (308 vs 264 
vs 268 minutes, p < 0.001), but TLE was done with less loss of blood (320 vs 536 vs 680 g, p < 
0.001). The postoperative hospital stay, duration of epidural anesthesia, and length of oxygen 
therapy were shorter in the TLE group. There were no difference in residual tumor or in the 
duration of ICU stay.  
 
Respiratory and overall complications 
Respiratory complications occurred in nine patients (13%) in TLE group, 13 patients 
(38%) in TE group, and 31 patients (39%) in OE group (Table 3). Overall complications 
occurred in 34 patients (47%), 20 patients (58%), and 54 patients (68%), respectively. The 
proportions of patients who required reoperation were similar. One patient in the TLE group, 
three in the TE group, and three in the OE group had reoperations due to anastomotic leakage, 
and one patient in the TLE group had a reoperation due to a chylothorax. All patients in all 
groups survived longer than 30 days after the operation. 
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The details of postoperative complications within 30 days are shown in Table 4. A total of 
14 respiratory adverse events occurred in the TLE group, 21 occurred in the TE group, and 36 
occurred in the OE group. For overall adverse events, the totals were 50, 42, and 81, respectively. 
In the bivariate analyses, having respiratory complications was associated with age, 
ASA-PS, history of smoking, pathological T stage, colon conduit, and with having undergone 
OE rather than TLE (Table 5). Having respiratory complications was not associated with having 
undergone OE rather than TE. In the multivariate analyses, having respiratory complications was 
associated with having undergone OE rather than TLE (adjusted odds ratio [AOR] = 0.22; 95% 
confidence interval [CI] 0.09-0.53; p = 0.001). 
In the bivariate analyses, having at least one of the overall complications was associated 
with ASA-PS, history of smoking, pathological T stage, colon conduit, and with having 
undergone OE rather than TLE (Table 6). In the multivariate analyses, having undergone TLE 
was associated with a lower adjusted odds of having one or more of the overall complications 
(AOR = 0.47; 95% CI 0.23-0.94; p = 0.034). 
 
Relapse-free survival 
The median follow-up time was 26 months (range: 3 to 63) in the TLE group, 24 months (4 to 
51) in the TE group, and 50 months (3 to 95) in the OE group. The 2-year RFS percentages were 
71.6%, 57.7%, and 58.3%, respectively. The RFS curve for TLE group was slightly higher than 
the curves for the other groups (Figure 2; TLE vs OE: p = 0.079; TE vs OE: p = 0.845 by 





Both TE and TLE were associated with acceptable mid-term oncological outcomes, but 
only the TLE group had lower odds of postoperative respiratory and overall complications than 
the OE group. In comparison to OE, laparoscopy might result in more rapid recovery of bowel 
function, easier postoperative ambulation, and thus also easier expectoration of respiratory 
secretions. This is consistent with post-gastrectomy findings that laparoscopy results in less 
impaired pulmonary function [15] and fewer pulmonary complications [16] than do open 
procedures. In addition, thoracoscopic surgery can minimize damage to the chest wall, which 
will preserve lung and chest-wall compliance. It can also provide a better operative field and 
easier identification of the mediastinal structures, for more precise dissection. 
Use of the prone position during thoracoscopy may promote hemostasis [10] and 
decrease lung injury. The mediastinum is exposed because bloody exudate flows out from the 
chest cavity by gravity, and thus does not conceal the operative field. The lung collapses because 
of the positive pressure pneumothorax, so lung retraction is not necessary. The overall result is 
less blood loss and fewer respiratory complications. The finding that TE alone was not associated 
with fewer postoperative complications indicates that the combination of laparoscopic and 
thoracoscopic surgery may synergistically reduce postoperative pain and restriction to breathing, 
resulting in fewer respiratory complications. 
Three previous studies have compared the results of TLE, TE, and OE. The present 
results are consistent with the report in which the percentage of patients with postoperative 
pulmonary complications was significantly lower in the TLE group (6.7%) than in the other two 
groups (20% for TE, 30% for OE) [8]. The other two studies did not show such a benefit of TLE 
[6, 9]. This inconsistency between studies may be related to study designs: First, we used a 
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relatively broad definition of “respiratory complication.” Second, the previous reports did not 
give details of the clinicopathological characteristics of the patients who underwent the three 
procedures, and likely confounders for respiratory complication such as age, history of smoking, 
and ASA-PS were not considered [17-19]. In contrast, our analyses included adjustments for 
likely confounders, which should provide stronger evidence of the superiority of TLE in terms of 
postoperative complications. 
The patients who underwent TLE were less likely to have overall complications (Table 6) 
than were those who underwent OE (both bivariate and multivariate analyses). The only 
exception was palsy of the recurrent laryngeal nerve, which was more common in the TLE group 
than in the other groups. All cases of this complication were CTCAE grade 2, which required 
testing and follow-up but were not aggravated. In this context we note that the prone position 
was more frequently used during TLE than during TE. The prone position provides better visual 
control than does the left decubitus position. When patients are in the prone position the lymph 
nodes are more clearly seen, and therefore the nodes might have been more aggressively 
dissected from the recurrent nerve, which could account for the higher incidence of recurrent 
laryngeal nerve palsy in TLE group. This does not mitigate the advantage of TLE, but of course 
more attention should be given to the dissection of lymph nodes around the recurrent laryngeal 
nerve to minimize the risk of injury. 
The advantages of TLE were not accompanied by any compromise in 2-year RFS. The 
Kaplan-Meier curve for RFS after TLE was the best of the three curves, although that might have 
been due to there being slightly more patients with N0-stage tumors in the TLE group. The 
survival advantage for TLE that was seen in the bivariate analysis was attenuated after 
adjustment for likely confounders. Thus, with regard to oncological outcome we consider TLE 
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and OE to be comparable, and we note that decisions to use the newer technique (TLE) therefore 
do not require any compromise with regard to that outcome. We are aware of no previous 
comparative studies in which RFS was evaluated. In two previous studies there were no 
differences in overall survival between TLE and OE [8, 9], although the numbers of patients in 
the TLE groups of those studies were relatively small (19 and 30 patients), so reasonable 
comparisons between techniques are difficult. The next question is whether TLE affects 
long-term survival, and this question requires further follow-up. 
There are several limitations in our study. First, the 30-day mortality and in-hospital 
mortality were zero in this study and could not be used as main outcomes. We presume that the 
major reason was the fact that patients were not included if they had undergone chemoradiation 
therapy, or had a T4 tumor. Second, there were several imbalances in important clinical 
characteristics between the groups. For example, no patients in the TLE group underwent 
reconstruction with a colon conduit, which might have resulted in confounding. We tried to 
adjust for these imbalances by using multivariate analyses, but there could be residual 
confounding. However, in previous studies the type of reconstruction conduit (colon vs stomach) 
did not affect the safety of esophagectomy [20, 21]. Third, our main outcomes are susceptible to 
bias. To minimize bias regarding the ascertainment of the main outcomes, the data reviewers 
were blinded to the surgical procedures. Finally, the duration of follow-up was limited. Still, the 
majority of recurrences develop within one year, and more than 90% of them develop by the 
third year after surgery [22, 23]. Thus, we believe that our follow-up period was long enough for 
comparing RFS among the groups. 
We conclude that in patients with esophageal cancer TLE, but not TE, was associated 
with fewer postoperative complications than OE, with no compromise of mid-term RFS. These 
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findings support the hypothesis that the combination of thoracoscopy with laparoscopy has a 
benefit greater than that of thoracoscopy alone. A randomized controlled trial with longer 
follow-up is needed. 
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Legends for figures 
 
Figure 1 
Numbers of patients who underwent each surgical procedure each calendar year. TLE: 




Kaplan-Meier curves for relapse-free survival in the three groups: TLE (combination of 
thoracoscopy and laparoscopy), TE (thoracoscopy and laparotomy), and OE (open 




Table 1. Clinical and pathological characteristics 
 TLE TE OE  
Variable (n = 72) (n = 34) (n = 79) p 
Age 62.7 ± 7.4 64.2 ± 8.8 63.3 ± 8.6 0.700
a
 
Sex (male : female) 58 : 14 29 : 5 70 : 9 0.385
b
 
Body mass index 20.0 ± 3.0 19.5 ± 2.8 20.6 ± 3.0 0.180
a
 
ASA-PS         0.846
c
 
I 35 (48%) 15 (44%) 36 (46%)  
II 37 (52%) 19 (53%) 41 (51%)  
III 0 (0%) 0 (0%) 2 (3%)  
History of smoking  57 (79%) 31 (91%) 64 (81%) 0.302
b
 
FEV1% (%) 75.2 ± 7.4 74.7 ± 10.2 77.1 ± 10.3 0.325
a
 
Mean serum albumin (mg/dL) 4.1 ± 0.3 3.9 ± 0.4 4.1 ± 0.4 0.021
a
 
Neoadjuvant chemotherapy 41 (57%) 13 (38%) 11 (14%) < 0.001
b
 
Tumor site    0.769
b
 
Upper  13 (18%) 8 (24%) 12 (15%)  
Middle 35 (49%) 15 (44%) 35 (44%)  
Lower 24 (33%) 11 (32%) 32 (41%)  
Histologic diagnosis     0.037
b
 
Squamous cell carcinoma 71 (99%) 31 (91%) 71 (90%)  
Adenocarcinoma 0 (0%) 3 (9%) 3 (4%)  
Other 1 (1%) 0 (0%) 5 (6%)  
Pathological T stage    0.528
b
 
T1, 2 41 (57%) 16 (47%) 46 (58%)  
T3, 4 31 (43%) 18 (53%) 33 (42%)  
Pathological N stage    0.242
b
 
N0 35 (49%) 13 (38%) 28 (35%)  
N1 37 (51%) 21 (62%) 51 (65%)  
Pathological M stage    0.511
b
 
M0 63 (88%) 27 (79%) 65 (82%)  
M1a, 1b 9 (12%) 7 (21%) 14 (18%)  
Pathological stage    0.487
c
 
I 21 (29%) 11 (32%) 18 (23%)  
IIA, B 26 (36%) 7 (21%) 27 (34%)  
III 16 (22%) 9 (26%) 20 (25%)  
IVA, B 9 (13%) 7 (21%) 14 (18%)  
Continuous variables are reported as mean ± SD. Abbreviations: ASA: American Society of 
Anesthesiology Classification, FEV1%: forced expiratory volume in 1 second as a percentage of 








Table 2. Surgical procedures 
 TLE TE OE  
Variable (n = 72) (n = 34) (n = 79) p 
Conduit    0.001
a
 
Stomach 72 (100%) 27 (79%) 66 (84%)  
Colon 0 (0%) 7 (21%) 13 (16%)  
Field of lymphadenectomy    0.093
a
 
Two fields 57 (79%) 25 (74%) 50 (63%)  
Three fields 15 (21%) 9 (26%) 29 (37%)  
Site of anastomosis    < 0.001
a
 
Neck 73 (100%) 34 (100%) 63 (80%)  
Thoracic cavity 0 (0%) 0 (0%) 16 (20%)  
Method of anastomosis    < 0.001
a
 
Hand-sewing 66 (92%) 22 (65%) 9 (11%)  




Table 3. Surgical outcomes 
 TLE TE OE  
 (n = 72) (n = 34) (n = 79) p 
Procedure-related variable     
Operative blood loss (g) 320 (25 - 1930) 536 (75 - 1530) 680 (190 – 4040) < 0.001a 
Duration of thoracic 
procedure (min) 
308 ± 73 264 ± 46 268 ± 80 < 0.001
b
 
Lymph nodes removed 
(intrathoracic) 
28 (2 - 50) 24 (3 - 64) 18 (1 - 56) 0.002
a
 
Residual tumor    0.499
c
 
R0 66 (92%) 31 (91%) 68 (86%)  
R1-R2 6 (8%) 3 (9%) 11 (14%)  
Conversion during 
thoracic procedure 
2 (3%) 1 (3%) -  
Postoperative course     
Duration of ICU 
stay (days) 
1 (1 – 3) 1 (1 – 8) 1 (1 – 8) 0.114 a 
Duration of epidural 
analgesia (days) 
4.4 ± 1.4 4.7 ± 1.3 6.2 ± 1.8 < 0.001
b
 
Duration of oxygen 
therapy (days) 
9.2 ± 4.1 10.6 ± 3.7 17.3 ± 8.8 < 0.001
b
 
Duration of hospital 
stay (days) 
23 (13 - 100) 32 (17 - 147) 53 (22 - 412) < 0.001
a
 
Complications within 30 days     
Respiratory complication 9 (13%) 13 (38%) 31 (39%) 0.001
c
 
Overall complication 34 (47%) 20 (58%) 54 (68%) 0.031
c
 
Reoperation 2 (3%) 3 (9%) 3 (4%) 0.344
c
 
Mortality within 30 days 0 0 0  
5 
Operative blood loss, lymph nodes removed, and durations of ICU stay and hospital stay are 






Chi-square test.  
6 
Table 4. Details of postoperative complications within 30 days 
  TLE (n = 72)  TE (n = 34)   OE (n = 79) 
 Number of 
events 
Grade (CTCAE)  Number 
of events 
Grade (CTCAE)  Number of 
events 
Grade (CTCAE) 
  2 3 4  2 3 4   2 3 4 
Respiratory complications               
ARDS 0 (0%) 0 0 0  1 (3%) 0 0 1  0 (0%) 0 0 0 
Atelectasis 3 (4%) 2 0 1  7 (21%) 6 0 1  16 (20%) 16 0 0 
Pneumonia 5 (7%) 5 0 0  10 (29%) 8 2 0  7 (9%) 7 0 0 
Pleural effusion 0 (0%) 0 0 0  1 (3%) 1 0 0  9 (11%) 9 0 0 
Bronchopulmonary 
hemorrhage 
0 (0%) 0 0 0 
 
0 (0%) 0 0 0  0 (0%) 0 0 0 
Pneumothorax 0 (0%) 0 0 0  0 (0%) 0 0 0  2 (3%) 1 1 0 
Respiratory tract fistula 1 (1%) 1 0 0  0 (0%) 0 0 0  0 (0%) 0 0 0 
Cough 2 (3%) 2 0 0  0 (0%) 0 0 0  1 (1%) 1 0 0 
Hiccups 0 (0%) 0 0 0  0 (0%) 0 0 0  0 (0%) 0 0 0 
Aspiration 3 (4%) 2 1 0  2 (6%) 2 0 0  1 (1%) 1 0 0 
Other complications               
Arrhythmia 7 (10%) 7 0 0  3 (9%) 3 0 0  5 (6%) 4 1 0 
Chylothorax 1 (1%) 0 1 0  0 (0%) 0 0 0  0 (0%) 0 0 0 
Diarrhea 0 (0%) 0 0 0  1 (3%) 1 0 0  3 (4%) 3 0 0 
Ileus 1 (1%) 0 1 0  0 (0%) 0 0 0  2 (3%) 1 1 0 
Anastomotic leakage 3 (4%) 2 1 0  8 (24%) 5 3 0  13 (17%) 10 3 0 
Anastomotic stenosis 4 (6%) 4 0 0  2 (6%) 2 0 0  3 (4%) 3 0 0 
Liver dysfunction 2 (3%) 2 0 0  1 (3%) 1 0 0  1 (1%) 1 0 0 
Wound infection 1 (1%) 1 0 0  2 (6%) 2 0 0  8 (10%) 8 0 0 
Palsy of the recurrent 
laryngeal nerve 
17 (23%) 17 0 0 
 
4 (12%) 4 0 0   10 (13%) 10 0 0 
Abbreviations: ARDS: adult respiratory distress syndrome, CTCAE: Common terminology criteria for adverse events. 
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Table 5. Bivariate and multivariate analyses of respiratory complications (n = 185)
 
 
  Bivariate  Multivariate 
Variable Categories or units OR (95%CI) p  AOR (95%CI) p 
Procedure       
TE TE vs OE 0.96 (0.42-2.19) 0.920  0.71 (0.29-1.76) 0.464 
TLE TLE vs OE 0.22 (0.10-0.51) < 0.001  0.22 (0.09-0.53) 0.001 
Age per year 1.05 (1.01-1.09) 0.020  1.03 (0.99-1.08) 0.174 
Sex female vs male 0.64 (0.24-1.68) 0.362    
Body mass index per kg/m
2
 1.02 (0.91-1.14) 0.708    
ASA-PS  II, III vs 1 2.07 (1.06-4.01) 0.032  1.58 (0.73-3.42) 0.244 
Serum albumin per g/dL 0.63 (0.26-1.51) 0.298    
FEV1%  per percent 0.97 (0.93-1.00) 0.088  0.98 (0.94-1.02) 0.336 
History of smoking yes vs no 3.45 (1.15-10.4) 0.027  3.10 (0.94-10.3) 0.066 
History of neoadjuvant 
chemotherapy 
yes vs no 0.65 (0.32-1.30) 0.219    
Pathological T stage T3, 4 vs T1, 2 2.01 (1.05-3.83) 0.035  1.83 (0.86-3.91) 0.119 
Pathological N stage N1 vs N0 1.93 (0.98-3.80) 0.058  1.32 (0.60-2.90) 0.492 
Conduit colon vs stomach 2.84 (1.11-7.28) 0.030  1.69 (0.59-4.88) 0.332 
Site of anastomosis neck vs thoracic cavity 1.56 (0.54-4.53) 0.416    
Abbreviations: OR: odds ratio, AOR: adjusted odds ratio, CI: confidence interval, ASA: American Society of Anesthesiology 
Classification, FEV1%: forced expiratory volume in 1 second as a percent of forced vital capacity. 
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Table 6. Bivariate and multivariate analyses of overall complications (n = 185)
 
 
  Bivariate  Multivariate 
Variable Categories or units OR (95%CI) p  AOR (95%CI) p 
Procedure       
TE TE vs OE 0.66 (0.29-1.52) 0.330  0.51 (0.21-1.25) 0.143 
TLE TLE vs OE 0.41 (0.21-0.80) 0.009  0.47 (0.23-0.94) 0.034 
Age per year 1.02 (0.98-1.06) 0.296    
Sex female vs male 0.67 (0.30-1.50) 0.331    
Body mass index per kg/m
2
 1.04 (0.94-1.16) 0.399    
ASA-PS  II, III vs 1 2.10 (1.16-3.80) 0.015  1.97 (1.05-3.71) 0.034 
Serum albumin Per g/dL 0.65 (0.29-1.49) 0.310    
FEV1%  per percent 0.99 (0.95-1.02) 0.376    
History of smoking yes vs no 2.20 (1.02-4.72) 0.043  1.87 (0.83-4.21) 0.130 
History of neoadjuvant 
chemotherapy 
yes vs no 0.91 (0.49-1.68) 0.768    
Pathological T stage T3, 4 vs T1, 2 1.92 (1.05-3.50) 0.033  2.08 (1.10-3.93) 0.025 
Pathological N stage N1 vs N0 1.24 (0.69-2.25) 0.473    
Conduit colon vs stomach 4.61 (1.30-16.3) 0.018  3.51 (0.92-13.3) 0.065 
Site of anastomosis neck vs thoracic cavity 0.91 (0.32-2.56) 0.857    
Abbreviations: OR: odds ratio, AOR: adjusted odds ratio, CI: confidence interval, ASA: American Society of Anesthesiology 
Classification, FEV1%: forced expiratory volume in 1 second as a percent of forced vital capacity. 
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Table 7. Bivariate and multivariate analyses of relapse-free survival (n = 165)
 
 
  Bivariate  Multivariate 




Procedure       
TE TE vs OE 1.07 (0.56-2.07) 0.834  0.91 (0.45-1.82) 0.781 
TLE TLE vs OE 0.58 (0.32-1.06) 0.079  0.65 (0.35-1.20) 0.176 
Age per year 1.00 (0.97-1.03) 0.994    
Sex female vs male 1.03 (0.52-2.02) 0.941    
ASA-PS  II, III vs 1 0.62 (0.37-1.04) 0.068  0.57 (0.33-0.96) 0.036 
Serum albumin per g/dL 0.56 (0.28-1.10) 0.094  0.81 (0.40-1.63) 0.553 
History of neoadjuvant 
chemotherapy 
yes vs no 0.69 (0.38-1.25) 0.219    
Field of lymphadenectomy 3 fields vs 2 fields 1.43 (0.84-2.44) 0.192  0.98 (0.56-1.69) 0.933 
Pathological T stage T3, 4 vs T1, 2 2.24 (1.33-3.76) 0.002  1.59 (0.91-2.79) 0.106 
Pathological N stage N1 vs N0 4.53 (2.35-8.76) < 0.001  3.91 (1.98-7.74) < 0.001 
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Supplementary material 1. List of postoperative complications and CTCAE grade 
  Grade (CTCAE) 
  2 3 4 
Respiratory complication 
ARDS  - Present, intubation not indicated Present, intubation indicated 
Atelectasis  Symptomatic, medical intervention indicated Operative intervention indicated 
Life-threatening respiratory 
compromise 
Pneumonia  Symptomatic, not interfering with ADL 




Pleural effusion  
Symptomatic, intervention such 
as diuretics or up to 2 therapeutic 
thoracenteses indicated 
Symptomatic and supplemental 
oxygen, >2 therapeutic thoracenteses, 
tube drainage, or pleurodesis indicated 
Life-threatening 
   
Bronchopulmonary 
hemorrhage 
 Symptomatic and medical intervention indicated  
Transfusion, interventional radiology, 
endoscopic, or operative intervention 
indicated ; radiation therapy 
Life-threatening 
consequences; major urgent 
intervention indicated 
Pneumothorax  Symptomatic; intervention indicated 




ventilatory support indicated 
Respiratory tract 
Fistula  
Symptomatic, tube thoracostomy 
or medical management 
indicated; associated with altered 
respiratory function but not 
interfering with ADL 
Symptomatic and associated with 
altered respiratory function interfering 
with ADL; or endoscopic or primary 





thoracoplasty, chronic open 
drainage or multiple 
thoracotomies indicated 
Cough  Symptomatic and narcotic medication indicated 
Symptomatic and significantly 
interfering with sleep or ADL - 
Hiccups  - Symptomatic, intervention indicated Symptomatic, significantly interfering with sleep or ADL 
Aspiration  Symptomatic ; medical intervention indicated 
Clinical or radiographic signs of 
pneumonia or pneumonitis; unable to 
aliment orally 
Life-threatening 
     
2 
     
Other complication 
Arrhythmia  Non-urgent medical intervention indicated 
Symptomatic and incompletely 
controlled medically, or controlled 
with device 
Life-threatening 
Chylothorax  Symptomatic; thoracentesis or tube drainage indicated Operative intervention indicated Life-threatening 
Diarrhea  
Increase of 4-6 stools 
per day over baseline; IV fluids 
indicated < 24 hrs; not interfering 
with ADL 
Increase of ≥7 stools per day over 
baseline; incontinence; IV fluids ≥ 
24 hrs; hospitalization; interfering 
with ADL 
Life-threatening 
Ileus  Symptomatic; altered GI function; IV fluids indicated <24 hrs 
Symptomatic and severely altered 
GI function; IV fluids, tube feeding, 






Symptomatic and interfering with 





Symptomatic; altered GI function; 
IV fluids indicated <24 hrs 
Symptomatic and severely altered 
GI function; IV fluids, tube 
feedings, or TPN indicated ≥24 hrs; 
operative intervention indicated 
Life-threatening; Operative 
intervention requiring complete 
organ resection 
Liver dysfunction  Jaundice Asterixis Encephalopathy or coma 
Wound infection  Localized, local intervention indicated 
IV antibiotic, antifungal, or 
antiviral intervention indicated; 
interventional radiology or 
operative intervention indicated 
Life-threatening 




Symptomatic, but not interfering 
with ADL; intervention not 
indicated 
Symptomatic, interfering 
with ADL; intervention indicated 
Life-threatening; tracheostomy 
indicated 
Abbreviations: CTCAE: Common terminology criteria for adverse events, ARDS: adult respiratory distress syndrome, IV: intravenous, 
GI: gastrointestinal, TPN: total parenteral nutrition. 
